Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRS3 | P32247 | 5/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.32 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.32 |
| ▸ | DCUN1D2 | Q6PH85 | 1/20 | 0.31 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8339323 | 0.85 | ESR1 (0.41) | BRS3ESR1 | |
| SCHEMBL6955822 | 0.84 | TP53 (0.41) | AGTR1AGTR2 | |
| SCHEMBL1773521 | 0.82 | FYN (0.39) | AGTR1AGTR2DCUN1D2DCUN1D1 | |
| SCHEMBL6961100 | 0.81 | NPC1 (0.39) | AGTR1AGTR2 | |
| SCHEMBL29366164 | 0.81 | TRPA1 (0.35) | AGTR1AGTR2DCUN1D2DCUN1D1 | |
| SCHEMBL21034528 | 0.81 | DCUN1D1 (0.33) | AGTR1AGTR2DCUN1D2DCUN1D1 | |
| SCHEMBL1132111 | 0.81 | TAAR1 (0.43) | — | |
| SCHEMBL6962635 | 0.81 | AKT1 (0.36) | AGTR1AGTR2DCUN1D2DCUN1D1 | |
| SCHEMBL3376281 | 0.81 | TRPA1 (0.35) | AGTR1AGTR2DCUN1D2DCUN1D1 | |
| SCHEMBL19222672 | 0.80 | S1PR1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286917-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-20230286917-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-11639333-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC (US) | 2023-05-02 | — | — | US | disclosed |
| US-11639333-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC (US) | 2023-05-02 | — | — | US | disclosed |
| US-11214542-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2022-01-04 | — | — | US | disclosed |
| US-20210009520-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2021-01-14 | — | — | US | disclosed |
| US-10807956-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-20200172485-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-06-04 | — | — | US | disclosed |
| US-10597365-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| US-20190077758-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-03-14 | — | — | US | disclosed |
| US-9611221-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| US-9611221-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| US-20160347714-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2016-12-01 | — | — | US | disclosed |
| US-9447045-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-20160115131-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC | 2016-04-28 | — | — | US | disclosed |
| US-20150291529-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2015-10-15 | — | — | US | disclosed |
| US-9085534-B2 | Histone demethylase inhibitors | Quanticel Pharmaceuticals, Inc. (US) | 2015-07-21 | — | — | US | disclosed |
| US-20150119397-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2015-04-30 | — | — | US | disclosed |
| US-8952151-B2 | Histone demethylase inhibitors | Quanticel Pharmaceuticals, Inc. (US) | 2015-02-10 | — | — | US | disclosed |
| US-20140213591-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2014-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077758-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5A, KDM1A | BRS3 2770/4885ESR1 1231/4885AGTR1 2977/4885 |
| US-11214542-B2 | Histone demethylase inhibitors | KDM1B, KDM5A, KDM1A | BRS3 2770/4885ESR1 1231/4885AGTR1 2977/4885 |
| US-20160115131-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5A, KDM1A | BRS3 2770/4885ESR1 1231/4885AGTR1 2977/4885 |
| US-20160347714-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5A, KDM1A | BRS3 2770/4885ESR1 1231/4885AGTR1 2977/4885 |
| US-10807956-B2 | Histone demethylase inhibitors | KDM1B, KDM5A, KDM1A | BRS3 2770/4885ESR1 1231/4885AGTR1 2977/4885 |
| US-20230286917-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5A, KDM1A | BRS3 2770/4885ESR1 1231/4885AGTR1 2977/4885 |
| US-20210009520-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5A, KDM1A | BRS3 2770/4885ESR1 1231/4885AGTR1 2977/4885 |
| US-11639333-B2 | Histone demethylase inhibitors | KDM1B, KDM5A, KDM1A | BRS3 2770/4885ESR1 1231/4885AGTR1 2977/4885 |
| US-20150119397-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5A, KDM1A | BRS3 2770/4885ESR1 1231/4885AGTR1 2977/4885 |
| US-20200172485-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5A, KDM1A | BRS3 2770/4885ESR1 1231/4885AGTR1 2977/4885 |
| US-20150291529-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5A, KDM1A | BRS3 2770/4885ESR1 1231/4885AGTR1 2977/4885 |
| US-20140213591-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5A, KDM1A | BRS3 2770/4885ESR1 1231/4885AGTR1 2977/4885 |
| US-10597365-B2 | Histone demethylase inhibitors | KDM1B, KDM5A, KDM1A | BRS3 2770/4885ESR1 1231/4885AGTR1 2977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.